Université Grenoble Alpes (UGA) is located in the middle of the Rhône-Alpes region, 2nd French region in terms of research activities.

UGA was born January 1st, 2016, from the merger of three Grenoble universities: Joseph Fourier University (UJF), Pierre Mendes France University (UPMF) and Stendhal University.

UGA is a research intensive university in an international and high tech environment:

  • 40 000 students;
  • 3 700 PhD students, 45% from abroad;
  • 2 200 permanent academic staff;
  • 80 laboratories organised in 6 research departments:
  • Mathematics, Sciences and Technologies of Information and Communication;
  • Chemistry, Biology, Health;
  • Physics of Particles, Astrophysics, Geosciences, Environment and Ecology;
  • Physics, Engineering, Materials;
  • Legal, Political and Economic Sciences, Territory Sciences, Sociology and Management;
  • Arts, Literature, Languages, Humanities, Cognitive and Social Sciences
  • 14 doctoral schools

In addition to 9 national organisms (CEA, CNRS, CEN/Météo-France, CRSSA, Inserm INRA, Inria, IRD, Irstea), the city hosts 5 large international research facilities (The European Synchrotron - ESRF, ILL, The European Molecular Biology Laboratory - EMBL, IRAM-Institute, GHMFL), that attract thousands of researchers every year.
Moreover, UJF benefits from an international recognition:

  • Shanghai Ranking 2015

Ranked 200, 7th French university, top 200 in natural sciences and mathematics, top 100 in Physics, and top 150in Engineering, technology and computer sciences. 

  • QS World university rankings 2014-2015, 7th French university, in the world’s top 250 (215th).
  • Taiwan ranking 2014: In the world’s top 200 (181th), 46th in Environment ( 1st French University), 72nd in Natural Sciences and 80th in Physics.
  • Times Higher Education Rankings 2014-2015: 7thth French University, UJF is the 178th best university worldwide. UJF is the top 100 for Physical science).


LBFA
Unité INSERM1055
Université de Grenoble
BP 53
38041 Grenoble Cedex 9

Department of Diabetology
Pôle DIGIDUNE
Grenoble University Hospital
CS 10217
38043 Grenoble Cedex 9

Center of Clinical Investigation
Grenoble University Hospital
CS 10217
38043 Grenoble Cedex 9

Website Grenoble University Hospital: www.chu-grenoble.fr


BIOCAPAN contact:
Dr. Sandrine Lablanche
Tel: +33476765836
Email : slablanche@chu-grenoble.fr


The people involved in the project are

Sandrine LablancheDr Sandrine Lablanche, Diabetologist, MD, PhD, invested in clinical islet transplantation trials, member of the GRAGIL Network, developing research on the involvement of mitochondria in human islet apoptosis and functionality.

Valeria A. JudkowskiDr Valeria A. Judkowski, PhD. Successfully managed international and multilingual teams as a Principal Investigator in Life and Biomedical Sciences. Extensive research and clinical experience in regulation of the immune response for the development and evaluation of preventive interventions and therapeutics in Infectious Diseases, Autoimmunity, and Cancer. 

Pierre-Yves BenhamouPr Pierre-Yves Benhamou, Diabetologist, MD, PhD, invested in islet transplantation for 20 years, is the scientific director of the GRAGIL network. The GRAGIL Network, one of the top five most active groups in islet transplantation worldwide, is a French-Swiss Network comprising several transplant centers (Besançon, Geneva, Grenoble, Lyon, Montpellier, Nantes, Nancy, Strasbourg) permitting pancreas procurement, recipient recruitment, transplant procedure and clinical follow-up in each center whereas islet isolation is performed in two facilities sharing the same procedure (Geneva and Grenoble). This group has allowed islet transplantation to be performed in more than one hundred patients with type 1 diabetes. Its latest trial, TRIMECO, was the first randomised controlled trial establishing the beneficial impact of islet transplantation on metabolic outcomes. Its next trial, STABILOT, will focus on medico-economical impact of this procedure.

Camille LaporteCamille Laporte is a PhD student implicated in the in vitro and in vivo performance evaluation of the BIOCAPAN capsules

Camille LaporteDr Sophie Althuser, PharmD and Head of project in clinical research. She belongs to the Center for Clinical Investigation (CIC - CHU Grenoble) and the Themas team (UJF). She has experience of many years in the regulatory aspects of biomedical clinical trials (epidemiology and technological innovation research projects) and is in charge of the respect of GCP (Good Clinical Practices) and ICH guidance. Research area : diabetes, vascular diseases, medical devices.

Emily TubbsEmily Tubbs, PhD., post doc implicated in the in vitro and in vivo performance evaluation of the BIOCAPAN capsules.